Across TCGA pan-cancer cohorts, YTHDF2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated YTHDF2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher YTHDF2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated YTHDF2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where YTHDF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.682	0.356	.004	24	view →
PDAC	OS	Median	IV	0.381	0.951	.006	18	view →
CCRCC	DFS	Quartile	All	0.607	1.000	.036	8	view →
HNSC	DFS	Median	III,IV	0.479	0.766	.002	8	view →
LSCC	DFS	Median	All	0.807	0.633	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: YTHDF2 tumor-vs-normal RNA expression · all YTHDF2 data types